IL-23/IL-17 psoriasis treatment study to understand skin immune changes
Treatments studied
Part of Skin clinical trials.
This study looks at what’s happening inside the body in people with plaque psoriasis who start certain biologic medicines that target the IL-23/IL-17 immune pathway. It may help explain why these treatments work and what body changes are linked to response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older) with skin psoriasis
- You can sign the consent form and follow study visits and instructions
- You need whole-body (systemic) treatment for your psoriasis
- You have not used biologic medicines before, or you’ve had at most one with at least a 4-month gap (for some groups)
- You are not already on, and have not previously received, an anti-IL-23 biologic
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the immune cells in skin samples from people with psoriasis who are being treated with an anti-IL-23 biologic. The goal is to understand why some areas of skin do not improve or why flares happen, which may help improve treatments.
This study looks at immune system differences in people with moderate-to-severe psoriasis. It aims to help guide more precise (targeted) treatment choices and may improve how well treatment works for you.
This study looks at how blood sugar control (including diabetes) changes immune cells in the skin for people with moderate to severe plaque psoriasis. It may help researchers understand what drives psoriasis and how it could respond to future treatments.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
This trial studies how guselkumab works for people with long-lasting, more severe psoriasis and signs that may affect joints. It may help by improving psoriasis symptoms and possibly reducing related inflammation, while researchers track safety and outcomes.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.